During the J.P. Morgan Healthcare Conference in San Francisco, Insulet highlighted that it achieved revenue growth at a compound annual growth rate (CAGR) of 25% between 2021-2025, with 2025 revenue coming to approximately $2.7bn.
Insulet also claimed to have driven 66% of the growth of the automated insulin delivery (AID) market during the last five years. These sales are wholly attributed to Insulet’s flagship product, the Omnipod 5, the first AID system FDA-cleared for type 1 and type 2 diabetes in the US. Insulet estimates their current total addressable market (TAM) for AID to be approximately 8 million people with diabetes, which translates to roughly $6bn in total market value and is anticipated to grow to $9bn by 2028. A growth plan is in place to develop new markets such as type 1 diabetes outside of the US, type 2 diabetes for basal-only treatment in the US as well as expanding coverage of type 1 diabetes in Asia, aiming to increase the TAM to approximately 17 million people with diabetes.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Insulet’s innovation roadmap includes enhancements to the Omnipod 5 ecosystem involving algorithm improvements, simplified onboarding and full integration with continuous glucose monitors. This will be followed by the Omnipod 6 which is expected to be launched in 2027 boasting improved clinical outcomes, better ease of use and connectivity. Lastly, the fully-closed loop system for type 2 diabetes is expected to launch in 2028 requiring no carbohydrate input for mealtime boluses.
The global insulin pump market was worth $7bn in 2025 and is expected to grow to $15.1bn by 2035 with a CAGR of 7.96%, according to GlobalData. This presents a significant opportunity to increase their market share as the patient population may look to AID systems instead of more traditional insulin pumps based on the benefits of utilizing a closed loop system for managing diabetes. Currently, Insulet makes up approximately 26% of the insulin pump market according to a GlobalData market model. As the diabetic population increases worldwide, growing awareness of the disease will demand further advancements in diabetes care devices. Insulet is in an advantageous market position as they aim to drive market penetration for type 1 and type 2 diabetes patients and expect to continue substantial growth based on their planned investment initiatives.
Sign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare Conference 2026.
Sign up here to receive a comprehensive report after the conference.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
